Literature DB >> 33517899

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma.

Yitao Gong1,2,3,4, Yunzhen Qian1,2,3,4, Guopei Luo1,2,3,4, Yu Liu1,2,3,4, Ruijie Wang1,2,3,4, Shengming Deng1,2,3,4, He Cheng1,2,3,4, Kaizhou Jin1,2,3,4, Quanxing Ni1,2,3,4, Xianjun Yu1,2,3,4, Weiding Wu5,6,7,8, Chen Liu9,10,11,12.   

Abstract

BACKGROUND: Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC). Therefore, we investigated the prognostic significance of GFPT1 expression in patients with resectable PDAC.
METHODS: We analyzed public datasets to compare GFPT1 expression in tumor tissues and normal/adjacent pancreatic tissues. We measured the relative GFPT1 expression of 134 resected PDAC specimens in our institution, using real-time polymerase chain reaction (PCR). Survival was compared between high and low GFPT1 expression groups using Kaplan-Meier curves and log-rank tests. Multivariate analyses were estimated using Cox regression and logistic regression models.
RESULTS: GFPT1 is generally upregulated in PDAC tissues, according to the analysis of public datasets. The data from our institution shows that high GFPT1 expression was correlated with a high rate of lymph node (LN) metastasis (p = 0.038) and was an independent risk factor for LN metastasis (odds ratio (OR) = 3.14, 95% confidence interval (CI) = 1.42 to 6.90, P = 0.005). High GFPT1 expression was significantly associated with poor overall survival (OS; P = 0.019) in patients with resected PDAC. The multivariable-adjusted hazard ratio (HR) for mortality when comparing patients with high and low GFPT1 expression was 2.54 (95% CI = 1.35 to 4.79, P = 0.004).
CONCLUSIONS: GFPT1 is generally upregulated in PDAC tissue and is associated with a high risk of LN metastasis and an unfavorable outcome in patients with resectable PDAC, suggesting its crucial role in PDAC progression.

Entities:  

Keywords:  Glutamine-fructose-6-phosphate transaminase 1; Hexosamine biosynthesis pathway (HBP); Prognosis; Survival

Mesh:

Substances:

Year:  2021        PMID: 33517899      PMCID: PMC7849098          DOI: 10.1186/s12957-021-02147-z

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  21 in total

1.  Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.

Authors:  Leandro M Colli; Mitchell J Machiela; Han Zhang; Timothy A Myers; Lea Jessop; Olivier Delattre; Kai Yu; Stephen J Chanock
Journal:  Cancer Res       Date:  2017-04-26       Impact factor: 12.701

2.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

Review 3.  Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review.

Authors:  Nickolay Fedchenko; Janin Reifenrath
Journal:  Diagn Pathol       Date:  2014-11-29       Impact factor: 2.644

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 5.  Molecular targeted therapy: Treating cancer with specificity.

Authors:  Yeuan Ting Lee; Yi Jer Tan; Chern Ein Oon
Journal:  Eur J Pharmacol       Date:  2018-07-20       Impact factor: 4.432

Review 6.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.

Authors:  Rushika M Perera; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2015-11-03       Impact factor: 39.397

Review 7.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2018-10-04       Impact factor: 41.582

8.  High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma.

Authors:  Lili Li; Miaomiao Shao; Peike Peng; Caiting Yang; Shushu Song; Fangfang Duan; Dongwei Jia; Mingming Zhang; Junjie Zhao; Ran Zhao; Weicheng Wu; Lan Wang; Can Li; Hao Wu; Jie Zhang; Xin Wu; Yuanyuan Ruan; Jianxin Gu
Journal:  Oncotarget       Date:  2017-03-21

Review 9.  Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer.

Authors:  Neha M Akella; Lorela Ciraku; Mauricio J Reginato
Journal:  BMC Biol       Date:  2019-07-04       Impact factor: 7.431

10.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.

Authors:  Zefang Tang; Boxi Kang; Chenwei Li; Tianxiang Chen; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

View more
  1 in total

1.  Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer.

Authors:  Chang Liu; Henan Qin; Huiying Liu; Tianfu Wei; Zeming Wu; Mengxue Shang; Haihua Liu; Aman Wang; Jiwei Liu; Dong Shang; Peiyuan Yin
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.